Loading
Autoimmune Skin Diseases / DNA Methylation / Non-coding RNA · Journal article
Journal of Translational Autoimmunity · August 14, 2026
A consensus or society position rather than new primary data.
This narrative review synthesizes current evidence on the role of epigenetic mechanisms—DNA methylation, histone lactylation, and non-coding RNAs—in autoimmune skin diseases including psoriasis, systemic lupus erythematosus, and scleroderma. The article proposes epigenetics as a regulatory 'pacemaker' linking genetic and environmental factors and suggests potential therapeutic and diagnostic applications, but presents no original clinical or empirical data to support practice change.
Narrative review article. Patients with autoimmune skin diseases, including systemic lupus erythematosus, dermatomyositis, systemic sclerosis, cutaneous lupus erythematosus, and psoriasis; general population context via twin studies.. China (author affiliations).
Monozygotic twin studies show incomplete disease concordance (approximately 4% in systemic sclerosis, 11–50% in systemic lupus erythematosus), indicating genetics alone does not explain autoimmune skin disease development Gene body methylation of Cathepsin G (CTSG) mediated by antisense lncRNA AL136018.1 recruits DNMT3a and increases CTSG expression in dermatomyositis with associated muscle inflammation lncRNAs including NRIR, HOTAIR, and PSMB8-AS1 regulate interferon-mediated responses, fibroblast death, and collagen synthesis in systemic sclerosis
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians and researchers should understand epigenetics as a potential framework for understanding disease pathogenesis and identifying biomarkers, but this review does not report clinical trial data or outcomes to guide treatment decisions. The proposed therapeutic targets (DNA methylation inhibitors, histone deacetylase inhibitors, JAK inhibitors) require validation in rigorous clinical studies before adoption.
A narrative review article synthesizing current knowledge on epigenetic mechanisms in autoimmune skin diseases, offering conceptual framework and therapeutic potential rather than reporting original empirical data or clinical trials.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians and researchers should understand epigenetics as a potential framework for understanding disease pathogenesis and identifying biomarkers, but this review does not report clinical trial data or outcomes to guide treatment decisions. The proposed therapeutic targets (DNA methylation inhibitors, histone deacetylase inhibitors, JAK inhibitors) require validation in rigorous clinical studies before adoption.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Autoimmune skin diseases, including psoriasis, cutaneous forms of systemic lupus erythematosus, and scleroderma, involve complicated interactions between genetic and environmental factors. Modern developments have pointed out the importance of regulatory epigenetic processes associated with DNA methylation, histone lactylation, and different types of non-coding RNA molecules like miRNA, lncRNAs, and circRNAs. Epigenetic factors serve as a "pacemaker" for immune cell activation, keratinocytes' function disturbances, and inflammatory microenvironment reconstruction. This review covers the role of epigenetics in development and progression of autoimmune skin diseases and shows its potential use for diagnostics, prediction, and treatment of these pathological conditions. Using the latest scientific results, the present article provides the necessary theoretical basis for the implementation of precision medicine methods in the treatment of autoimmune skin diseases.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.